Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BOSTON SCIENTIFIC CORP Director's Dealing 2023

Sep 21, 2023

29821_dirs_2023-09-21_76bb483a-417a-48a9-b752-3355458ea568.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BOSTON SCIENTIFIC CORP (BSX)
CIK: 0000885725
Period of Report: 2023-09-20

Reporting Person: Fitzgerald Joseph Michael (EVP & Group Pres, Cardiology)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2023-09-20 Common Stock S 15867.0000 $55.0000 Disposed 197992.0000 Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 68020.0000 Indirect
Common Stock 4344.0000 Indirect

Footnotes

F1: The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 15, 2023, intended to comply with the prior version of Rule 10b5-1(c).

F2: Balance reflects the most current data available with regard to share holdings in the Company's 401(k) Retirement Savings Plan.

F3: The reporting person disclaims beneficial ownership of the shares held by his child, and this report should not be deemed an admission that the reporting person is the beneficial owner of his child's shares for purposes of Section 16 or for any other purpose.